WHO Prequalification

In the competitive and highly regulated world of pharmaceuticals, getting your product prequalified by the World Health Organization (WHO) can unlock global procurement opportunities and boost your credibility.

What Is WHO Prequalification?

WHO Prequalification of Medicines Programme (PQP) is a service provided by WHO to assess the quality, safety, and efficacy of medicines. The goal is to ensure that only high-quality pharmaceuticals are procuread by United Nations agencies and other global health stakeholders.

The prequalification is especially relevant for multisource (generic) pharmaceutical products that aim to treat priority diseases such as HIV/AIDS, malaria, tuberculosis, and others. Once prequalified, your product is listed on the WHO website, making it eligible for purchase by international procurement agencies like UNICEF, the Global Fund, and others.

In essence, prequalification acts like a global passport for your medicine, allowing broader market access, increased visibility, and enhanced trust.

WHO Prequalification: The End-to-End Process

Getting prequalified is not just about filling out a form. It is a rigorous, multi-step process that evaluates your product’s quality, safety, efficacy, manufacturing site compliance, and regulatory documentation. Here’s how it works:

  1. Expression of Interest (EOI)
  2. Start by submitting an EOI in response to a call for medicines published by WHO. This outlines your intention to have a specific medicine evaluated and includes basic information about your product.
  1. Preparation of the Product Dossier (PD)
  2. You will need to compile a Product Dossier (PD) following the Common Technical Document (CTD) format. This is broken down into modules:
    • Module 1: Regional information (admin/legal).
    • Module 2: Quality Overall Summary (QOS-PD) — a concise summary of Module 3.
    • Module 3: Detailed data on quality aspects of the API and FPP (finished pharmaceutical product).
    Key sections include:
    • API details: manufacturing, quality control, stability.
    • FPP details: formulation, manufacturing process, specifications, container-closure system, and stability data.
    You can submit API info via:
    • WHO prequalified API
    • Certificate of Suitability (CEP)
    • API Master File (APIMF)
    • Full details in the dossier
  1. Dossier Assessment by WHO
  2. WHO conducts a scientific review of the dossier. This includes assessment of:
    • Compliance with ICH/WHO quality guidelines.
    • Consistency and completeness of data.
    • Adequacy of control measures.
  1. Manufacturing Site Inspection
  2. WHO conducts Good Manufacturing Practice (GMP) inspections at both the API and FPP manufacturing sites to ensure compliance with WHO GMP standards.
  1. Product Testing
  2. In some cases, WHO may also test product samples in a WHO-designated laboratory.
  1. Prequalification Decision
  2. If everything meets WHO requirements, your product is added to the List of Prequalified Medicinal Products, enabling you to participate in global health tenders.

Challenges Faced During Prequalification

Many applicants underestimate the amount of preparation needed. Common hurdles include:
  • Incomplete or inconsistent quality data
  • Non-alignment with WHO’s CTD format
  • Insufficient GMP documentation
  • Inadequate validation of analytical methods
  • Missing or weak stability data
These gaps can delay your approval or lead to outright rejection.

How Masuu Pharma Can Help You

At Masuu Pharma Quality and Regulatory Consultants, we specialize in guiding pharmaceutical companies through the complete WHO prequalification process — from initial planning to final approval.

Our services include:
  • Gap Analysis: We assess your existing documentation and processes against WHO requirements.
  • Dossier Preparation: We help build or revise CTD-compliant product dossiers (Modules 1–3).
  • Quality Strategy: We ensure your data on API and FPP (including stability, specifications, and validation) meet WHO standards.
  • GMP Readiness: We conduct mock inspections and train your team to prepare for WHO GMP audits.
  • Regulatory Submissions: We manage submissions and responses to WHO queries (screening and assessment phases).
  • Lifecycle Support: We assist with post-approval variations, renewals, and requalification.

With our deep knowledge of WHO TRS 970 Annex 4 and TRS 986 Annex 6 guidelines, we ensure that your dossier is technically sound, strategically structured, and submission-ready.

Frequently Asked Questions

The WHO Prequalification of Medicines Programme (PQP) is a WHO assessment process that evaluates the quality, safety, and efficacy of eligible medicines. Successful prequalification can increase a product’s credibility and support access to international procurement opportunities.

WHO Prequalification is particularly relevant to multisource (generic) medicines used to address priority public health needs, including treatments for diseases such as HIV/AIDS, malaria, and tuberculosis. Eligibility depends on the medicines included in WHO’s applicable calls for Expressions of Interest (EOIs).

The process generally begins with an Expression of Interest (EOI), followed by preparation and submission of the Product Dossier. WHO then conducts a scientific assessment, evaluates manufacturing sites for GMP compliance, and may conduct product testing before making a prequalification decision.

The Product Dossier follows the applicable CTD structure and includes administrative information and detailed quality documentation. Key sections cover the API and finished pharmaceutical product (FPP), including manufacturing processes, specifications, analytical controls, formulation, container-closure systems, and stability data.

API information can be supported through different approaches depending on the circumstances, including a WHO-prequalified API, Certificate of Suitability (CEP), API Master File (APIMF), or detailed API information within the product dossier. The appropriate approach should be selected based on applicable WHO requirements.

WHO reviews the submitted information for quality, consistency, completeness, manufacturing controls, analytical methods, stability, and compliance with applicable WHO and international quality standards. The assessment may result in questions or requests for additional information from the applicant.

WHO may inspect relevant API and finished-product manufacturing facilities to assess compliance with applicable WHO GMP requirements. Applicants should therefore ensure that their manufacturing processes, quality systems, documentation, and personnel are prepared for a regulatory inspection.

Product testing may be performed in appropriate circumstances using samples assessed through WHO-designated laboratories. Testing can provide additional assurance that the product meets the required quality standards and specifications.

Applicants may face challenges such as incomplete quality data, inconsistent dossier information, inadequate GMP documentation, insufficient analytical method validation, or weak stability data. Conducting a thorough gap assessment before submission can help identify and address these issues early.

Masuu Pharma provides end-to-end support covering gap analysis, CTD Product Dossier preparation, API and FPP quality strategy, GMP readiness and mock inspections, WHO submission support, responses to regulatory queries, and lifecycle activities such as variations, renewals, and requalification. Our team helps ensure that the dossier and manufacturing systems are technically prepared for WHO assessment.

Book a Demo